Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TENX Stock Forecast 2026-2027
$18.27
Current Price
$114.07M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TENX Price Targets
+64.2%
To High Target of $30.00
+36.8%
To Median Target of $25.00
-26.0%
To Low Target of $13.52
TENX Price Momentum
+39.3%
1 Week Change
+72.2%
1 Month Change
+181.9%
1 Year Change
+49.9%
Year-to-Date Change
-0.6%
From 52W High of $18.38
+294.6%
From 52W Low of $4.63
📊 TOP ANALYST CALLS
Did TENX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tenax is one of their latest high-conviction picks.
Latest TENX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, TENX has a bullish consensus with a median price target of $25.00 (ranging from $13.52 to $30.00). The overall analyst rating is N/A (N/A/10). Currently trading at $18.27, the median forecast implies a 36.8% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Aschoff at Roth MKM, projecting a 64.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TENX Analyst Ratings
5
Buy
0
Hold
0
Sell
TENX Price Target Range
Low
$13.52
Average
$25.00
High
$30.00
Current: $18.27
Latest TENX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TENX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 17, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $25.00 |
| Sep 8, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $20.00 |
| Aug 14, 2025 | Guggenheim | Seamus Fernandez | Buy | Maintains | $14.00 |
| Oct 24, 2024 | Leerink Partners | David Risinger | Outperform | Initiates | $16.00 |
| Oct 14, 2024 | Guggenheim | Seamus Fernandez | Buy | Initiates | $16.00 |
| Sep 30, 2024 | William Blair | Matt Phipps | Outperform | Initiates | $N/A |
| Feb 20, 2024 | Roth MKM | Jonathan Aschoff | Buy | Reiterates | $30.00 |
| Nov 13, 2023 | Roth MKM | Jonathan Aschoff | Buy | Reiterates | $6.00 |
| Mar 7, 2023 | Roth MKM | Jonathan Aschoff | Buy | Initiates | $6.00 |
| Dec 29, 2020 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $5.00 |
| May 18, 2017 | Ladenburg Thalmann | Buy | Upgrade | $N/A |
Tenax Therapeutics Inc. (TENX) Competitors
The following stocks are similar to Tenax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tenax Therapeutics Inc. (TENX) Financial Data
Tenax Therapeutics Inc. has a market capitalization of $114.07M with a P/E ratio of 2.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -44.8%.
Valuation Metrics
Market Cap
$114.07M
Enterprise Value
$511.21M
P/E Ratio
2.4x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.4%
Current Ratio
15.6x
Debt/Equity
0.0x
ROE
-44.8%
ROA
-29.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tenax Therapeutics Inc. (TENX) Business Model
About Tenax Therapeutics Inc.
What They Do
Pharmaceutical company focused on critical care treatments.
Business Model
Tenax Therapeutics generates revenue by developing and commercializing clinical-stage treatments for cardiopulmonary diseases. The company focuses on addressing unmet medical needs through innovative drug development and is engaged in conducting clinical trials to bring new therapies to market.
Additional Information
Based in the United States, Tenax Therapeutics is dedicated to advancing novel drug formulations that may significantly improve patient outcomes in severe cardiovascular and pulmonary conditions, contributing to the overall biopharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. Christopher T. Giordano
Country
United States
IPO Year
1995
Website
www.tenaxthera.comTenax Therapeutics Inc. (TENX) Latest News & Analysis
Latest News
Tenax Therapeutics: A Speculative Buy
6 days ago
Quick Summary
Tenax Therapeutics is rated a speculative BUY, with levosimendan showing potential for PH-HFpEF. The Phase III trial has a 60-70% success chance, supporting a $450M market cap.
Why It Matters
Tenax Therapeutics presents a potentially lucrative investment with levosimendan's promising Phase III trial, balanced by manageable risks and a market cap that aligns with conservative revenue projections.
Source: Seeking Alpha
Market Sentiment:
Neutral
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
9 days ago
Quick Summary
Tenax Therapeutics (TENX) has a Buy rating and $25 price target, indicating 127% upside. TNX-103 shows strong Phase 2 efficacy and 65% success probability for Phase 3. Peak sales estimated at $500M by 2035.
Why It Matters
Tenax Therapeutics' Buy rating and $25 price target suggest significant upside potential. Promising drug TNX-103's Phase 3 success probability enhances investor confidence in future revenues.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Tenax Therapeutics' LEVEL study is on track for enrollment completion in H1 2026, with topline data expected in H2 2026. The LEVEL-2 study has started, aiming for enrollment completion by end of 2027.
Why It Matters
The successful sample size re-estimation boosts confidence in the LEVEL study's efficacy, enhancing Tenax Therapeutics' credibility and potential stock value as it nears critical data milestones.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenax Therapeutics (Nasdaq: TENX) will present at upcoming investor conferences as it develops novel cardiopulmonary therapies in Phase 3 trials.
Why It Matters
Tenax Therapeutics presenting at investor conferences signals potential interest and engagement, which could influence stock price and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2 months ago
Quick Summary
The Phase 3 LEVEL study is ongoing, with enrollment of 230 patients expected to complete by mid-2026. Topline data is anticipated in the second half of 2026.
Why It Matters
The ongoing Phase 3 LEVEL Study with a clear timeline for patient enrollment and data release may impact the company's valuation, stock price, and investor sentiment based on results.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenax Therapeutics discussed the scientific rationale and development strategy for TNX-103 in treating pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF) during a recent call.
Why It Matters
Tenax Therapeutics' focus on TNX-103 for PH-HFpEF signals potential advancements in treatment, impacting stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About TENX Stock
What is Tenax Therapeutics Inc.'s (TENX) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Tenax Therapeutics Inc. (TENX) has a median price target of $25.00. The highest price target is $30.00 and the lowest is $13.52.
Is TENX stock a good investment in 2026?
According to current analyst ratings, TENX has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TENX stock?
Wall Street analysts predict TENX stock could reach $25.00 in the next 12 months. This represents a 36.8% increase from the current price of $18.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tenax Therapeutics Inc.'s business model?
Tenax Therapeutics generates revenue by developing and commercializing clinical-stage treatments for cardiopulmonary diseases. The company focuses on addressing unmet medical needs through innovative drug development and is engaged in conducting clinical trials to bring new therapies to market.
What is the highest forecasted price for TENX Tenax Therapeutics Inc.?
The highest price target for TENX is $30.00 from Jonathan Aschoff at Roth MKM, which represents a 64.2% increase from the current price of $18.27.
What is the lowest forecasted price for TENX Tenax Therapeutics Inc.?
The lowest price target for TENX is $13.52 from at , which represents a -26.0% decrease from the current price of $18.27.
What is the overall TENX consensus from analysts for Tenax Therapeutics Inc.?
The overall analyst consensus for TENX is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are TENX stock price projections?
Stock price projections, including those for Tenax Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 4:31 AM UTC